Search

Investigators at MSK are developing new immunotherapy treatments that rely on engineering T cells to recognize mutated proteins that are unique to cancer.

Learn how MSK researchers are investigating the use of nanoparticles to carry drugs across the blood-brain barrier.

Scientists and scholars received degrees and awards at MSK's 40th annual ceremony, held on May 29.

Learn how the Pediatric Translational Medicine Program at Memorial Sloan Kettering is bringing together experts to make new discoveries about pediatric cancer.

The in-person event featured scientific talks from leading women in science, including winners of this year’s Kravis WISE fellowships.

The incidence of mouth and throat cancer is on the rise due to oral transmission of the human papilloma virus, but the "silver lining" of this phenomenon is doctors at Memorial Sloan Kettering have significantly reduced the intensity of treatment while achieving excellent outcomes for these patients.

In an effort to expand and streamline patient access to its high-quality cancer care, Memorial Sloan Kettering Cancer Center has introduced MSK Direct, a unique program in which MSK collaborates with external employers to simplify how their employees can engage with us for initial or ongoing cancer care.

Harold Varmus became President and Chief Executive Officer of Memorial Sloan Kettering Cancer Center on January 1, 2000. He ended his decade-long tenure on July 1, 2010. And on July 12, 2010, Dr. Varmus took up a new role as Director of the National Cancer Institute.